title: [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
abstract: A study has claimed that at equal elemental calcium dose, CaCO3 was not less but equally efficient in controlling predialysis hyperphosphatemia as calcium acetate provided both calcium salts were given five minutes before the meals instead of during the meals because the higher acidity of a fasting gastric juice would allow a better dissociation of CaCO3. To examine the point that CaCO3 is more efficient if it is taken five minutes before compared to during the meal, we performed a two month randomised cross-over trial in twelve reliable and stable patients maintained on chronic hemodialysis while their treatment and diet remained constant. Comparison of the plasma concentrations measured during the two modes of administration showed no significant difference in creatinine, urea, bicarbonate, intact-PTH. Mean (+/- SD) plasma PO4 was significantly higher (1.93 +/- 0.50 versus 1.72 +/- 0.40 mmol/l; p = 0.02) whereas corrected plasma Ca was significantly lower (2.30 +/- 0.15 versus 2.38 +/- 0.17 mmol/l; p = 0.01) when CaCO3 was given before the meals than during the meals.
  
  
  CONCLUSIONS
  a) administration of CaCO3 before the meal decreases its efficiency in controlling hyperphosphatemia since plasma PO4 was actually slightly higher with this timing of administration; b) administration of CaCO3 before the meal is associated with significantly lower plasma corrected calcium suggesting a smaller absorption of calcium which may be an advantage but only in hypercalcemic patients; c) there is no reason other than the prevention of its hypercalcemic effect to recommend the administration of CaCO3 just before the meals than during the meals.
authors.affiliation: Service de néphrologie, CHU Sud, Amiens.
authors.forename: A
authors.initials: A
authors.lastname: Séchet
authors.forename: O
authors.initials: O
authors.lastname: Abighanem
authors.forename: S
authors.initials: S
authors.lastname: Said
authors.forename: M
authors.initials: M
authors.lastname: Rasombololona
authors.forename: P
authors.initials: P
authors.lastname: Morinière
authors.forename: M
authors.initials: M
authors.lastname: Brazier
authors.forename: A
authors.initials: A
authors.lastname: Fournier
mesh_terms: D000368:Aged; D001639:Bicarbonates / Q000097:blood; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004435:Eating; D005215:Fasting; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood*; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D001639:Bicarbonates; D010281:Parathyroid Hormone; D010710:Phosphates; D002119:Calcium Carbonate; D002118:Calcium